Alnylam Pharmaceuticals (NASDAQ:ALNY) Q3 results:
Revenues: $70.1M (+999%); Onpattro sales: $46.1M (+999%).
Net loss: ($208.5M) (+15.0%); loss/share: ($1.92) (+21.0%).
Over 600 patients worldwide on Onpattro. Product launches in Japan and Canada underway.
Topline data from Phase 3 ILLUMINATE-A study evaluating lumasiran in primary hyperoxaluria Type 1 should be available by year-end.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.